肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效

Clinical Efficacy of Pulmonary Surfactant in the Treatment of Neonatal Respiratory Distress Syndrome

目的探讨肺表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效。方法选取2014年7月—2017年9月我院收治的57例呼吸窘迫综合征患儿作为研究对象。按照随机数字法,将其分为观察组(29例)和对照组(28例)。对照组采用常规治疗,观察组在对照组的基础上,采用肺表面活性物质治疗,对比两组患者的治疗效果。结果观察组患者的治疗总有效率高于对照组,差异具有统计学意义(P<0.05);观察组血气指标改善情况优于对照组,差异具有统计学意义(P<0.05)。结论将肺表面活性物质应用于新生儿呼吸窘迫症的治疗中可以提高临床治疗效果,改善患儿的血气指标,安全性更高。

Objective To investigate the clinical efficacy of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome.Methods 57 children with respiratory distress syndrome treated in our hospital from July 2014 to September 2017 were selected as the subjects.According to the random number method,they were divided into the observation group(29 cases)and the control group(28 cases).The control group was treated with routine treatment.The observation group was treated with pulmonary surfactant on the basis of the control group.The treatment effect of two groups of patients was compared.Results The total effective rate of treatment in the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).The improvement of blood gas index in the observation group was better than that of the control group,and the difference was statistically significant(P<0.05).Conclusion The application of pulmonary surfactant in the treatment of neonatal respiratory distress syndrome can improve the clinical therapeutic effect and improve the blood gas index and safety of children.